在转移性卵巢黑色素瘤中使用Tebentafusp的三年整体存活率
Jessica C Hassel1, Sophie Piperno-Neumann1, Piotr Rutkowski1
1From the University Hospital Heidelberg, Heidelberg (J.C.H.), the Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University of Munich, Munich (M.S.), and the Department of Dermatology, Venereology, and Allergology (M.S.) and the Department of Hematology, Oncology, and Tumor Immunology and the Comprehensive Cancer Center (S.O.), Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and the Department of Hematology, Oncology, and Tumor Immunology and the Comprehensive Cancer Center, Berlin Institute of Health (S.O.), Berlin - all in Germany; Institut Curie, Paris (S.P.-N.), and Centre Antoine Lacassagne, Nice (L.G.) - both in France; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland (P.R.); Institut Roi Albert II Cliniques Universitaires St-Luc, Université Catholique de Louvain, Brussels (J.-F.B.); Princess Margaret Cancer Centre, the Department of Medical Oncology and Hematology, and the Department of Immunology, University of Toronto, Toronto (M.O.B.); Massachusetts General Hospital and Dana-Farber Cancer Institute - both in Boston (R.J.S.); University of Zürich Hospital, Zürich, Switzerland (R.D.); University of Pittsburgh Medical Center, Pittsburgh (J.M.K.), Sidney Kimmel Cancer Center, Jefferson University, Philadelphia (M.O.), and Immunocore, Conshohocken (C.P.) - all in Pennsylvania; the Clatterbridge Cancer Centre NHS Foundation Trust, Wirral (J.J.S.), University of Liverpool, Liverpool (J.J.S.), Immunocore, Abingdon-on-Thames (L.C.), and Mount Vernon Cancer Centre, Northwood and UCLH, London (P.N.) - all in the United Kingdom; Kinghorn Cancer Centre, Saint Vincent's Hospital, Darlinghurst, NSW, Australia (A.M.J.); Providence Portland Medical Center, Portland, OR (B. Curti); Institut Català d'Oncologia and the Cancer Immunotherapy Group, OncoBell, Institut d'Investigació Biomèdica de Bellvitge, Barcelona, and Centro de Investigación Biomédica en Red de Cáncer, Madrid - all in Spain (J.M.P.); Duke University, Durham, NC (A.K.S.S.); Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York (A.N.S.), and Northwell Health Cancer Institute, New Hyde Park (R.D.C.) - all in New York; N.N. Blokhin National Medical Research Center of Oncology, Moscow (L.D.); University of Iowa Hospitals and Clinics, Iowa City (M.M.); Jonsson Comprehensive Cancer Center, University of California (B. Chmielowski), and the Angeles Clinic and Research Institute, Cedars-Sinai Affiliate (O.H.), Los Angeles, and California Pacific Medical Center, San Francisco (K.B.K.); and Immunocore, Rockville, MD (K.R., C.H.).
在转移性脑膜黑色素瘤患者中,Tebentafusp显示出显著的长期生存益处. 与研究人员相比,这种双特异性分子提供了改善的整体存活率.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 眼科医生 眼科 眼科
背景情况:
- Tebentafusp是一种经批准的T细胞受体双特异分子,向糖蛋白100和CD3.
- 它适用于HLA-A*02:01阳性成年患者,患有不可切除或转移的皮膜黑色素瘤.
- 以前的分析表明,使用tebentafusp治疗的长期生存优势.
研究的目的:
- 报告tebentafusp在转移性皮膜黑色素瘤中的3年疗效和安全结果.
- 评估tebentafusp与标准疗法相比的长期生存益处.
主要方法:
- 一项开放的第三阶段试验随机选择了HLA-A*02:01阳性的未经治疗的转移性乳膜黑色素瘤患者 (2:1比率).
- 患者接受了tebentafusp或研究人员的选择 (pembrolizumab,ipilimumab或dacarbazine).
- 随机化被乳酸脱酶水平分层;整体存活率是主要终点.
主要成果:
- 治疗tebentafusp的中位总生存时间为21.6个月,对照组为16.9个月 (HR 0.68).
- 对于tebentafusp,三年生存率为27%,对照组为18%.
- 常见的不良事件包括皮疹,发烧和;大多数是早期的和可控的,停药率低 (2%vs5%).
结论:
- 在成年患者中,Tebentafusp提供了持续的长期整体存活益处,这些患者患有转移性脑膜黑色素瘤.
- 安全性概况与长期使用保持一致,没有观察到新的不良事件.
- 这项研究证实tebentafusp是这个患者群体的有价值的治疗选择.


